On June 27, 2026, Cuu Long Pharmaceutical Joint Stock Company (DCL) was honored with the Top 10 Outstanding Enterprises for Socio-Economic Development 2026 award. The recognition was presented as part of a program jointly organized by the Institute for Development Issues, the Institute of Economics and Culture, and the Vietnam Consumer Protection Center, honoring businesses that have made significant contributions to production, business development, job creation, and sustainable economic growth.
The award recognizes DCL’s continuous efforts to strengthen its manufacturing capabilities, drive technological innovation, and contribute to the advancement of Vietnam’s pharmaceutical industry as well as local economic development. Throughout its 50-year history, DCL has remained committed to its mission of providing high-quality pharmaceutical products, improving community healthcare, and creating sustainable value for society.
Ms. Nguyen Thi Thu Huong, Chief Executive Officer of DCL, receives the Top 10 Outstanding Enterprises for Socio-Economic Development 2026 award.
In addition to maintaining steady business growth, DCL has consistently invested in expanding its manufacturing capacity, modernizing its production facilities, and enhancing corporate governance. The company is currently implementing several strategic projects designed to meet the increasingly stringent standards of the pharmaceutical industry while laying a strong foundation for long-term growth and strengthening its competitiveness in both domestic and international markets.
Beyond business performance, DCL considers people to be the cornerstone of sustainable development. The company is committed to fostering a professional working environment where employees are encouraged to learn, develop their capabilities, and maximize their potential. At the same time, DCL actively participates in community initiatives, reflecting its commitment to corporate social responsibility and promoting meaningful social values.
Speaking at the award ceremony, Ms. Nguyen Thi Thu Huong, Chief Executive Officer of DCL, remarked: “Being recognized among the Top 10 Outstanding Enterprises for Socio-Economic Development 2026 is a tremendous honor and a meaningful acknowledgment of the dedication and hard work of all DCL employees. This recognition also motivates us to remain committed to our sustainable development strategy—placing quality at the core of everything we do, putting people at the center of our growth, and continuously innovating to create meaningful value for our customers, partners, employees, and the community.”
Ms. Nguyen Thi Thu Huong shares her remarks during the award ceremony.
As Vietnam’s pharmaceutical industry continues to evolve in response to greater integration and innovation, DCL remains focused on investing in advanced technologies, strengthening research and product development capabilities, and building a modern management system as key strategic priorities. At the same time, the company continues to invest in developing high-quality human resources, accelerating digital transformation, and optimizing manufacturing operations to improve efficiency and better meet the evolving needs of the market.
Being named among the Top 10 Outstanding Enterprises for Socio-Economic Development 2026 is not only recognition of DCL’s achievements but also a powerful source of motivation for the company to continue pursuing sustainable growth. Backed by 50 years of development, a well-defined investment strategy, and a relentless commitment to innovation, DCL will continue contributing to the advancement of Vietnam’s pharmaceutical industry, generating greater value for the economy, and supporting the long-term mission of improving community healthcare.
